NVDA
NVIDIA Corporation
NVDA has the edge over OTEX overall, supported by stronger modeled upside and stronger fundamentals.
OTEX
Open Text Corporation
OTEX trails on the overall score without a compensating advantage in the available component scores.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
OTEX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Under pressure |
OTEX's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over OTEX in the historical PE scenario, which offers more potential upside but is not a forecast.
OTEX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 6.4x | $24.81 | — |
| Current | 9.4x | $24.81 | — |
| Cheap | 14x | $35.71 | +44% |
| Fair | 31x | $83.11 | +235% |
| Expensive | 53x | $139 | +462% |
Historical ranges are pointers, not guarantees.
OTEX's PE is in its cheap range at 9.4x. On analysts' estimates for next year's earnings, today's price would be 6.4x.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
NVDA has the edge over OTEX on the outlook, with more favorable earnings and revenue expectations.
OTEX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Weakening | |
| Limited | |
| High |
Analysts expect OTEX's profitability to weaken, with its earnings and revenue holding steady.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over OTEX on earnings, with more consistent year-over-year improvement.
OTEX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.86 | +46% |
| Q3 2026 | $2.64 | +38% |
| Q2 2026 | $2.58 | +56% |
| Q1 2026 | $2.05 | -16% |
| Q4 2025 | $1.70 | -31% |
| Q3 2025 | $1.91 | +10% |
| Q2 2025 | $1.65 | -3.5% |
| Q1 2025 | $2.45 | +295% |
| Q4 2024 | $2.46 | +423% |
OTEX earned $2.64 per share over the past year, up 38% from the year before.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over OTEX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over OTEX on profitability, with a higher operating margin.
OTEX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2B | -4% |
| Q2 2026 | $1.3B | +2.9% |
| Q1 2026 | $1.3B | +2.2% |
| Q4 2025 | $1.3B | -0.6% |
| Q3 2025 | $1.3B | +1.5% |
| Q2 2025 | $1.3B | -3.8% |
| Q1 2025 | $1.3B | -13% |
| Q4 2024 | $1.3B | -13% |
OTEX's revenue fell from its 2023 peak and has held roughly level since: $1.2B last quarter, down 4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -0.7 points |
| Q2 2026 | 24% | +9.8 points |
| Q1 2026 | 16% | -1 points |
| Q4 2025 | 22% | -0.2 points |
| Q3 2025 | 21% | +4.7 points |
| Q2 2025 | 14% | -0.3 points |
| Q1 2025 | 17% | +1 points |
| Q4 2024 | 22% | +5.6 points |
OTEX's operating margin was 20% last quarter, down 0.7 points from the same quarter a year ago.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over OTEX on cash flow, with more consistent year-over-year improvement.
OTEX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $138.5M | +37% |
| Q2 2026 | $122M | -1.6% |
| Q1 2026 | $304.9M | -18% |
| Q4 2025 | $279.4M | -8.9% |
| Q3 2025 | $101.2M | +$218.4M |
| Q2 2025 | $124M | -15% |
| Q1 2025 | $373.8M | +7.4% |
| Q4 2024 | $306.7M | +0.4% |
OTEX generated $845M in free cash flow over the past year, down 6.7% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
OTEX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.9% | -7.3M shares |
| 1 year | -4.6% | -11.7M shares |
| 3 years | -11% | -29.8M shares |
| 5 years | -11% | -31.1M shares |
| Available history | -11% | -29.5M shares |
OTEX has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $30M |
| Q2 2026 | $11.8M |
| Q1 2026 | $247M |
| Q4 2025 | $50M |
| Q3 2025 | $107.6M |
| Q2 2025 | $145.3M |
| Q1 2025 | $114.6M |
| Q4 2024 | $66M |
OTEX spent $339M buying back its own shares over the past year, down 22% from the year before.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over OTEX on leverage, with a lower net debt burden relative to earnings.
OTEX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.2x | Elevated |
| Q2 2026 | 3.2x | Elevated |
| Q1 2026 | 3.6x | Elevated |
| Q4 2025 | 3.6x | Elevated |
| Q3 2025 | 3.8x | Elevated |
| Q2 2025 | 3.9x | Elevated |
| Q1 2025 | 3.7x | Elevated |
| Q4 2024 | 3.7x | Elevated |
OTEX's net debt is about 3.2 years of its operating earnings (EBITDA), down from 3.8 years a year ago.
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
OTEX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 57.4 | Neutral |
OTEX's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
OTEX PE vs Technology Sector
| Metric | OTEX | Sector median | Relative |
|---|---|---|---|
| PE | 9.4x | 28x | 66% below |
| PE % | 2 | 35 | 33 pts below |
OTEX has the edge over NVDA on valuation relative to its sector.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
OTEX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $24.8 | 0.2% above |
| 20 week MA | $24.2 | 2.5% above |
| 50 week MA | $25.1 | 1.1% below |
| 100 week MA | $27.6 | 10% below |
| 200 week MA | $31.8 | 22% below |
OTEX has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over OTEX on returns for 2026, with the stronger performance.
OTEX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.1 | $45.7 | +3.8% |
| 2021 | $45.7 | $47.4 | +3.6% |
| 2022 | $47.4 | $29.0 | -39% |
| 2023 | $29.0 | $42.0 | +45% |
| 2024 | $42.0 | $28.3 | -33% |
| 2025 | $28.3 | $33.5 | +18% |
| 2026 YTD | $33.5 | $24.8 | -26% |
OTEX has finished higher in four of the last six years. It's down 26% so far in 2026.